IP Library › Granted Patent US 12708665
Granted Patent B2
US 12708665 · App. 17/763,780 · Granted Aug 18, 2026

Anti-IL-1β antibody therapy in arrhythmogenic cardiomyopathy (ACM)

Inventor: Jeffrey E. Saffitz (Waban, MA)
Assignee: Beth Israel Deaconess Medical Center, Inc.
A61K39/3955A61P9/06A61P29/00A61P9/00C07K14/545C07K16/245C07K2317/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12708665
App. No.
17/763,780
Granted
Aug 18, 2026
Kind
B2
Abstract

Described herein are, inter alia, methods for treating arrhythmogenic cardiomyopathy (ACM) using anti-inflammatory agents that IL-1β.

Claims (9)

1 . A method of treating a human subject with arrhythmogenic cardiomyopathy (ACM), the method comprising:

(a) identifying a human subject as having or at risk of developing ACM; and

(b) administering to the human subject a therapeutically effective amount of an anti-interleukin-1β (IL-1β) antibody selected from the group consisting of canakinumab, APX002, and XOMA052.

2 . The method of claim 1 , wherein the anti-IL-1β antibody is canakinumab.

3 . The method of claim 1 , wherein the anti-IL-1β antibody is APX002.

4 . The method of claim 1 , wherein the anti-IL-1β antibody is XOMA052.

5 . The method of claim 1 , wherein step (a) comprises determining that the human subject has a desmoglein-2 (DSG2) deficiency.

6 . The method of claim 5 , wherein determining that the human subject has a desmoglein-2 (DSG2) deficiency comprises determining that the human subject has a mutation in the DSG2 gene, or by measuring the level of DSG2 protein.

7 . The method of claim 1 , wherein step (b) comprises injecting the IL-1β antibody in the human subject.